Target intelligence / Profile preview

Ovarian cancer–associated antigen OC166-9

Molecular classification: Tumor-associated antigen, Surface antigen

Overview

OC166-9 is an ovarian cancer–associated antigen targeted in immunotherapy research. It is expressed on ovarian carcinoma cells and serves as a target for adoptive cell therapies and monoclonal antibody development, such as with the 6B11 antibody. Targeting OC166-9 aims to induce both humoral and cellular immunity against tumors.

Other names: OC166-9

Mechanism of action

Targeting of tumor cells for immune-mediated destruction.

Biological functions

Tumor cell recognitionImmune response modulation

Disease associations

CancerOvarian Cancer

Safety considerations

Potential for off-target effects of immunotherapyCytokine release syndromeTumor lysis syndrome

Biomarkers

OC166-9 expression level in tumor tissue

Beyond the preview

Go deeper on Ovarian cancer–associated antigen OC166-9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ovarian cancer–associated antigen OC166-9.

Explore the full profile